JP6663993B2 - 安定性が向上し、取り込みが改善されたホノキオール及びマグノロール製剤、並びにそれらの使用方法 - Google Patents

安定性が向上し、取り込みが改善されたホノキオール及びマグノロール製剤、並びにそれらの使用方法 Download PDF

Info

Publication number
JP6663993B2
JP6663993B2 JP2018528109A JP2018528109A JP6663993B2 JP 6663993 B2 JP6663993 B2 JP 6663993B2 JP 2018528109 A JP2018528109 A JP 2018528109A JP 2018528109 A JP2018528109 A JP 2018528109A JP 6663993 B2 JP6663993 B2 JP 6663993B2
Authority
JP
Japan
Prior art keywords
formulation
honokiol
magnolol
disorder
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018528109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528266A (ja
JP2018528266A5 (enExample
Inventor
ピー フラムローゼ ボミ
ピー フラムローゼ ボミ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST IP Holding AG
Original Assignee
ST IP Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST IP Holding AG filed Critical ST IP Holding AG
Publication of JP2018528266A publication Critical patent/JP2018528266A/ja
Publication of JP2018528266A5 publication Critical patent/JP2018528266A5/ja
Application granted granted Critical
Publication of JP6663993B2 publication Critical patent/JP6663993B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018528109A 2015-08-17 2016-01-18 安定性が向上し、取り込みが改善されたホノキオール及びマグノロール製剤、並びにそれらの使用方法 Expired - Fee Related JP6663993B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2534DE2015 2015-08-17
IN2534/DEL/2015 2015-08-17
PCT/IN2016/050021 WO2017029683A1 (en) 2015-08-17 2016-01-18 Honokiol and magnolol formulations with increased stability and improved uptake, and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2018528266A JP2018528266A (ja) 2018-09-27
JP2018528266A5 JP2018528266A5 (enExample) 2019-02-21
JP6663993B2 true JP6663993B2 (ja) 2020-03-13

Family

ID=58051448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018528109A Expired - Fee Related JP6663993B2 (ja) 2015-08-17 2016-01-18 安定性が向上し、取り込みが改善されたホノキオール及びマグノロール製剤、並びにそれらの使用方法

Country Status (12)

Country Link
US (1) US10328090B2 (enExample)
EP (1) EP3337487B1 (enExample)
JP (1) JP6663993B2 (enExample)
KR (1) KR20180050331A (enExample)
AU (2) AU2016308080A1 (enExample)
CA (1) CA2995834A1 (enExample)
DK (1) DK3337487T3 (enExample)
ES (1) ES2873601T3 (enExample)
HU (1) HUE054161T2 (enExample)
PL (1) PL3337487T3 (enExample)
PT (1) PT3337487T (enExample)
WO (1) WO2017029683A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183141A1 (en) 2018-03-21 2019-09-26 Realtime Robotics, Inc. Motion planning of a robot for various environments and tasks and improved operation of same
KR20200083304A (ko) * 2018-12-28 2020-07-08 충북대학교 산학협력단 일본 목련 추출물을 유효성분으로 함유하는 불안장애의 예방 또는 치료용 약학적 조성물
WO2020154712A1 (en) * 2019-01-25 2020-07-30 Flaask, Llc Compositions and methods for improving quality of life in patients with autism spectrum disorder
CN110585140A (zh) * 2019-07-08 2019-12-20 苏州海特比奥生物技术有限公司 一种和厚朴酚纳米聚合物胶束冻干制剂及其制备方法
US12213505B2 (en) * 2021-07-05 2025-02-04 Healthy Ingredient Solutions, LLC Composition for promoting restful sleep and methods of making and using the same
WO2025136962A1 (en) * 2023-12-19 2025-06-26 Rebalance Health, Inc. Compositions for reducing hot flashes and symptoms associated with anxiety and formulations thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582735B2 (en) 2000-12-15 2003-06-24 Npi, Llc. Compositions and methods of use for extracts of magnoliaceae plants
US7632525B2 (en) 2002-06-25 2009-12-15 Wm. Wrigley Jr. Company Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents
CN1723011A (zh) 2002-06-25 2006-01-18 Wm·雷格利Jr·公司 含有厚朴提取物的口气清新和口腔清洁产品
CN101321537A (zh) 2005-12-02 2008-12-10 Gic创新公司 含厚朴提取物的糖食组合物
RU2396941C2 (ru) 2005-12-02 2010-08-20 Джи Ай Си ИННОВАТИОНЗ КОМПАНИ Наполнители с экстрактом коры магнолии для ухода за полостью рта
RU2398593C2 (ru) 2005-12-02 2010-09-10 Джи Ай Си ИННОВАТИОНЗ КОМПАНИ Жевательные составы с экстрактом коры магнолии быстрого высвобождения
BRPI0810435A2 (pt) 2007-04-19 2014-11-25 Mary Kay Inc Composições contendo extrato de magnólia
WO2011115476A1 (en) * 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
DE102010015791A1 (de) * 2010-04-20 2011-10-20 Beiersdorf Ag Wirkstoffkombinationen aus Magnolienrindenextrakt und polyethoxylierten Verbindungen
DE102010015792A1 (de) * 2010-04-20 2011-10-20 Beiersdorf Ag Wirkstoffkombinationen aus Magnolienrindenextrakt und oberflächenaktiven Agentien
EP2611313A1 (en) * 2010-09-03 2013-07-10 N.V. Nutricia Method and preparation for the treatment or prevention of anxiety or neurogenesis
FR2970294B1 (fr) * 2011-01-11 2012-12-28 Peugeot Citroen Automobiles Sa Ligne d'echappement pour un moteur a combustion interne
IE20110008A1 (en) 2011-01-12 2012-08-01 Patrick Thomas Prendergast Compositions for alleviating:- stress, anxiety, depression and aiding with weight loss
WO2013043151A1 (en) 2011-09-19 2013-03-28 Framroze Bomi P Edible oil with a high concentration of poly-unsaturated fatty acids
CA2849294C (en) * 2011-09-20 2023-03-21 Vivaquant Llc Physiological signal denoising

Also Published As

Publication number Publication date
PT3337487T (pt) 2021-05-27
WO2017029683A1 (en) 2017-02-23
KR20180050331A (ko) 2018-05-14
US20180147220A1 (en) 2018-05-31
EP3337487B1 (en) 2021-02-24
EP3337487A4 (en) 2019-04-03
DK3337487T3 (da) 2021-05-25
JP2018528266A (ja) 2018-09-27
US10328090B2 (en) 2019-06-25
AU2016308080A1 (en) 2018-03-22
PL3337487T3 (pl) 2021-12-06
EP3337487A1 (en) 2018-06-27
ES2873601T3 (es) 2021-11-03
AU2022201271A1 (en) 2022-03-17
CA2995834A1 (en) 2017-02-23
HUE054161T2 (hu) 2021-08-30

Similar Documents

Publication Publication Date Title
JP6663993B2 (ja) 安定性が向上し、取り込みが改善されたホノキオール及びマグノロール製剤、並びにそれらの使用方法
EP3630145A1 (en) Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use
JP2013517234A (ja) センシンレン（Ａｎｄｒｏｇｒａｐｈｉｃｓｐａｎｉｃｕｌａｔａ）抽出物と、リン脂質と複合体を形成した銀杏抽出物とを含む組成物
JP2006083151A (ja) 骨粗鬆症予防、改善用組成物
JP7655920B2 (ja) 認知障害の治療に使用する組成物
JPWO2020004357A1 (ja) アルツハイマー病の治療、予防又は改善用組成物、脳神経細胞死の抑制用組成物、アミロイドβペプチドで誘導されるミクログリアの活性化の抑制用組成物、及び、アミロイドβペプチドで誘導されるＰＧＥ２、ＴＮＦ−α又はＩＬ−１β産生の抑制用組成物
US8759547B2 (en) Extraction of vitamin E from plant matter
EP3189846A1 (en) Pharmaceutical composition for prevention or treatment neuro-inflammation or neurodegenerative diseases comprising Portulaca grandiflora Hook. extracts or fractions thereof
EP2712619B1 (en) Composition for preventing or treating dementia comprising extracts of monsonia species
JP5013659B2 (ja) アセチルコリンエステラーゼ阻害剤
JP5548379B2 (ja) 花粉荷を含有する抗ヒスタミン剤
JPH0662795A (ja) 抗アレルギー食品
JP2009249331A (ja) 植物由来の高脂血症の予防または改善剤
JP6398014B2 (ja) ラマリンを含有する退行性脳疾患の予防または治療用組成物
JP2004067526A (ja) アトピー性疾患の症状の予防・緩和に有効な組成物
CN119969583A (zh) 一种缓解抑郁的组合物及其制备方法和应用
JP7166965B2 (ja) ｂＦＧＦ発現増強用組成物
US20230219015A1 (en) Extraction method and mixture of substances
JP2006089387A (ja) 血液流動性改善剤
BR102021024155A2 (pt) Uso de uma solução/emulsão a partir de ziziphus cotinifolia reissek no tratamento dos transtornos da ansiedade
JPWO2005099485A1 (ja) 健康食品及びその製造方法、並びに乾燥物又は抽出物
CN116322651A (zh) 甲状腺素运载蛋白四聚体稳定化剂、以及甲状腺素运载蛋白淀粉样变性预防剂或进展抑制剂
US20180369134A1 (en) Compositions and Methods of Transdermal Delivery for Therapeutic Agents
JP2005289979A (ja) 神経成長因子合成促進剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200217

R150 Certificate of patent or registration of utility model

Ref document number: 6663993

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees